Sindrome.del.Ovario.Poliquistico

Fecundación in vitro 161
12
Fleming R, Hopkinson ZE, Wallace AM,
Greer IA, Sattar N. Ovarian function
and metabolic factors in women with
oligomenorhea treated with metformin
in a randomized double-blind, placebocontrolled
trial. J Clinic Endocrinol
Metab. 2002;87:569-74.
13
Haas DA, Carr BR, Attia GR. Effects
of metformin on body mass index,
menstrual cyclicity, and ovulation
induction in women with polycystis
ovary syndrome. Fertil Steril. 2003;79:
469-81.
14
Lord JM, Flight IHK, Norman RJ. Metformin
in polycystic ovary syndrome:
systematic review and meta-analysis. Br
Med J. 2003;327:25.
15
Nestler JE, Jakuowich DJ, Evans
WS, Pasquali R. Effects of metformin
on spontaneous and clomiphene
induced ovulation in the polycystic
ovary syndrome. N Eng J Med. 1998;338:
1876-80.
16
El-Biely MM, Habba M. The use of
metformin to augment the induction of
ovulation in obese infertile patients with
polycystic ovary syndrome. Middle East
Fertil Soc J. 2001;6:43-9.
17
Farhi J, Homburg R, Lerner A. The
choice of treatment for anovulation
following failure to conceive with clomiphene.
Hum Reprod. 1993;8:1367-71.
18
Homburg R, Howles CM. Low-dose
FSH therapy for anovulatory infertility
associated with polycystic ovary syndrome:
rationales, results, reflections
and refinements. Hum Reprod Update.
1999;5:493-9.
19
Franks S, Roberts R, Hurdy K. Gonadotropin
regimens and oocyte quality in
women with polycystic ovaries. Reprod
Biomed Online. 2002;6:181-4.
20
Hardy K, Robinson FM, Paraschos T,
Wicks R, Franks S, Winston RM. Normal
development and metabolic activity of
preimplantation embryos in vitro from
patients with polycystic ovaries. Hum
Reprod. 1995;10:2125-35.
21
Nugent D, Vandekerckhove P, Hughes
E, Arnot M, Lilford R. Gonadotrophin
therapy for ovulation induction in subfertility
associated with polycystic ovary
syndrome. Cochrane Database Syst Rev.
2000;(4):CD000410.
22
Van Wely M, Westergaard LG, Bossuyt
PM, Van der Veen F. Effectiveness of
human menopausal gonadotropin versus
recombinant follicle-stimulating
hormone for controlled ovarian hyperstimulation
in assisted reproductive
cycles: a meta-analysis. Fertil Steril.
2003;80:1086-93.
23
Daya S. Updated meta-analysis of recombinant
follicle-stimulating hormone
(FSH) versus urinary FSH for ovarian
stimulation in assisted reproduction.
Fertil Steril. 2002;77:711-4.
24
Al-Inany H, Aboulghar MA, Mansour R,
Serour G. Meta-analysis of recombinant
versus urinary-derived FSH: an update.
Hum Reprod. 2003;18:305-13.
25
Goldfarb JM, Desai N. Follitropin-alpha
versus human menopausal gonadotropin
in an in vitro fertilization program.
Fertil Steril. 2003;80:1094-9.
26
Homburg R, Levy T, Berkovitz D, Farchi
J, Feldberg D, Ashkenazi J, et al. Gonadotropin-releasing
hormone agonist
reduces the miscarriage rate for pregnancies
achieved in women with polycystic
ovarian syndrome. Fertil Steril.
1993;59:527-31.
27
Balen AH, Tan SL, MacDougall J,
Jacobs HS. Miscarriage rates following
in-vitro fertilization are increased
in women with polycystic ovaries and
reduced by pituitary desensitization
with buserelin. Hum Reprod. 1993;8:
959-64.
28
Hughes EG, Fedorkow DM, Daya S,
Sagle MA, Van de Koppel P, Collins
JA. The routine use of gonadotropinreleasing
hormone agonists prior to in
vitro fertilization and gamete intrafallopian
transfer: a meta-analysis of randomized
controlled trials. Fertil Steril.
1992;58:888-96.